The £4.6bn London Pensions Fund Authority (LPFA) has appointed Robert Vandersluis to its board as a non-executive director.
LPFA chairman Edi Truell said the appointment was part of the association’s plans to build its in-house capabilities and reduce its dependency on external advisers.
Vandersluis (pictured) is a director of global pension investments at GlaxoSmithKline (GSK) where he manages a large derivative and investment portfolio, as well as providing strategic advice to GSK’s trustees for pension funds in Europe, the US and Japan.
At GSK, Vandersluis has developed and overseen the implementation of the scheme’s interest rate and inflation hedging strategies, and established its London-based pension investment department.
At LPFA he will enhance the fund’s expertise in asset and liability management.
Prior to GSK, Vandersluis held senior positions at Affinity Sutton Group and Ford Credit Europe Bank. He has also served on the boards of five organisations, including The Pensions Trust.
Truell said: “One of the LPFA’s priorities at present is to build our in-house and board capabilities, reducing the need for external advisers. Robert has achieved an enormous amount in his career so far and will further enhance our credentials in asset and liability management and treasury management. We are delighted to be welcoming someone with his talent, expertise and passion to our board.”
Vandersluis added: “I am delighted to be invited to join the LPFA board. I look forward to working with the board and the corporate management team in helping to achieving the LPFA’s objective of delivering long-term sustainable pensions for generations to come.”
The appointment comes shortly after the release of the LPFA’s 2013 annual report, which showed that the fund grew by £427m during 2012-13, to £4.6bn.
Comments